BRCA1 and BRCA2 founder mutations account for 78% of germline carriers among hereditary breast cancer families in Chile

Carolina Alvarez, Teresa Tapia, Elisa Perez-Moreno, Patricia Gajardo-Meneses, Catalina Ruiz, Mabel Rios, Claudio Missarelli, Mariela Silva, Adolfo Cruz, Luis Matamala, Luis Carvajal-Carmona, Mauricio Camus, Pilar Carvallo

Research output: Contribution to journalArticle

10 Citations (Scopus)

Abstract

Identifying founder mutations in BRCA1 and BRCA2 in specific populations constitute a valuable opportunity for genetic screening. Several studies from different populations have reported recurrent and/or founder mutations representing a relevant proportion of BRCA mutation carriers. In Latin America, only few founder mutations have been described. We screened 453 Chilean patients with hereditary breast cancer for mutations in BRCA1 and BRCA2. For recurrent mutations, we genotyped 11 microsatellite markers in BRCA1 and BRCA2 in order to determine a founder effect through haplotype analysis. We found a total of 25 mutations (6 novel) in 71 index patients among which, nine are present exclusively in Chilean patients. Our analysis revealed the presence of nine founder mutations, 4 in BRCA1 and 5 in BRCA2, shared by 2 to 10 unrelated families and spread in different regions of Chile. Our panel contains the highest amount of founder mutations until today and represents the highest percentage (78%) of BRCA1 and BRCA2 mutation carriers. We suggest that the dramatic reduction of Amerindian population due to smallpox and wars with Spanish conquerors, a scarce population increase during 300 years, and the geographic position of Chile constituted a favorable scenario to establish founder genetic markers in our population.

Original languageEnglish (US)
Pages (from-to)74233-74243
Number of pages11
JournalOncotarget
Volume8
Issue number43
DOIs
StatePublished - 2017

Fingerprint

Chile
Breast Neoplasms
Mutation
Population
Founder Effect
Smallpox
Latin America
Genetic Testing
Genetic Markers
Microsatellite Repeats
Haplotypes

Keywords

  • BRCA1
  • BRCA2
  • Breast cancer
  • Chile
  • Founder mutation

ASJC Scopus subject areas

  • Oncology

Cite this

Alvarez, C., Tapia, T., Perez-Moreno, E., Gajardo-Meneses, P., Ruiz, C., Rios, M., ... Carvallo, P. (2017). BRCA1 and BRCA2 founder mutations account for 78% of germline carriers among hereditary breast cancer families in Chile. Oncotarget, 8(43), 74233-74243. https://doi.org/10.18632/oncotarget.18815

BRCA1 and BRCA2 founder mutations account for 78% of germline carriers among hereditary breast cancer families in Chile. / Alvarez, Carolina; Tapia, Teresa; Perez-Moreno, Elisa; Gajardo-Meneses, Patricia; Ruiz, Catalina; Rios, Mabel; Missarelli, Claudio; Silva, Mariela; Cruz, Adolfo; Matamala, Luis; Carvajal-Carmona, Luis; Camus, Mauricio; Carvallo, Pilar.

In: Oncotarget, Vol. 8, No. 43, 2017, p. 74233-74243.

Research output: Contribution to journalArticle

Alvarez, C, Tapia, T, Perez-Moreno, E, Gajardo-Meneses, P, Ruiz, C, Rios, M, Missarelli, C, Silva, M, Cruz, A, Matamala, L, Carvajal-Carmona, L, Camus, M & Carvallo, P 2017, 'BRCA1 and BRCA2 founder mutations account for 78% of germline carriers among hereditary breast cancer families in Chile', Oncotarget, vol. 8, no. 43, pp. 74233-74243. https://doi.org/10.18632/oncotarget.18815
Alvarez, Carolina ; Tapia, Teresa ; Perez-Moreno, Elisa ; Gajardo-Meneses, Patricia ; Ruiz, Catalina ; Rios, Mabel ; Missarelli, Claudio ; Silva, Mariela ; Cruz, Adolfo ; Matamala, Luis ; Carvajal-Carmona, Luis ; Camus, Mauricio ; Carvallo, Pilar. / BRCA1 and BRCA2 founder mutations account for 78% of germline carriers among hereditary breast cancer families in Chile. In: Oncotarget. 2017 ; Vol. 8, No. 43. pp. 74233-74243.
@article{5a5d043a31bd487690ece195ccce6c44,
title = "BRCA1 and BRCA2 founder mutations account for 78{\%} of germline carriers among hereditary breast cancer families in Chile",
abstract = "Identifying founder mutations in BRCA1 and BRCA2 in specific populations constitute a valuable opportunity for genetic screening. Several studies from different populations have reported recurrent and/or founder mutations representing a relevant proportion of BRCA mutation carriers. In Latin America, only few founder mutations have been described. We screened 453 Chilean patients with hereditary breast cancer for mutations in BRCA1 and BRCA2. For recurrent mutations, we genotyped 11 microsatellite markers in BRCA1 and BRCA2 in order to determine a founder effect through haplotype analysis. We found a total of 25 mutations (6 novel) in 71 index patients among which, nine are present exclusively in Chilean patients. Our analysis revealed the presence of nine founder mutations, 4 in BRCA1 and 5 in BRCA2, shared by 2 to 10 unrelated families and spread in different regions of Chile. Our panel contains the highest amount of founder mutations until today and represents the highest percentage (78{\%}) of BRCA1 and BRCA2 mutation carriers. We suggest that the dramatic reduction of Amerindian population due to smallpox and wars with Spanish conquerors, a scarce population increase during 300 years, and the geographic position of Chile constituted a favorable scenario to establish founder genetic markers in our population.",
keywords = "BRCA1, BRCA2, Breast cancer, Chile, Founder mutation",
author = "Carolina Alvarez and Teresa Tapia and Elisa Perez-Moreno and Patricia Gajardo-Meneses and Catalina Ruiz and Mabel Rios and Claudio Missarelli and Mariela Silva and Adolfo Cruz and Luis Matamala and Luis Carvajal-Carmona and Mauricio Camus and Pilar Carvallo",
year = "2017",
doi = "10.18632/oncotarget.18815",
language = "English (US)",
volume = "8",
pages = "74233--74243",
journal = "Oncotarget",
issn = "1949-2553",
publisher = "Impact Journals",
number = "43",

}

TY - JOUR

T1 - BRCA1 and BRCA2 founder mutations account for 78% of germline carriers among hereditary breast cancer families in Chile

AU - Alvarez, Carolina

AU - Tapia, Teresa

AU - Perez-Moreno, Elisa

AU - Gajardo-Meneses, Patricia

AU - Ruiz, Catalina

AU - Rios, Mabel

AU - Missarelli, Claudio

AU - Silva, Mariela

AU - Cruz, Adolfo

AU - Matamala, Luis

AU - Carvajal-Carmona, Luis

AU - Camus, Mauricio

AU - Carvallo, Pilar

PY - 2017

Y1 - 2017

N2 - Identifying founder mutations in BRCA1 and BRCA2 in specific populations constitute a valuable opportunity for genetic screening. Several studies from different populations have reported recurrent and/or founder mutations representing a relevant proportion of BRCA mutation carriers. In Latin America, only few founder mutations have been described. We screened 453 Chilean patients with hereditary breast cancer for mutations in BRCA1 and BRCA2. For recurrent mutations, we genotyped 11 microsatellite markers in BRCA1 and BRCA2 in order to determine a founder effect through haplotype analysis. We found a total of 25 mutations (6 novel) in 71 index patients among which, nine are present exclusively in Chilean patients. Our analysis revealed the presence of nine founder mutations, 4 in BRCA1 and 5 in BRCA2, shared by 2 to 10 unrelated families and spread in different regions of Chile. Our panel contains the highest amount of founder mutations until today and represents the highest percentage (78%) of BRCA1 and BRCA2 mutation carriers. We suggest that the dramatic reduction of Amerindian population due to smallpox and wars with Spanish conquerors, a scarce population increase during 300 years, and the geographic position of Chile constituted a favorable scenario to establish founder genetic markers in our population.

AB - Identifying founder mutations in BRCA1 and BRCA2 in specific populations constitute a valuable opportunity for genetic screening. Several studies from different populations have reported recurrent and/or founder mutations representing a relevant proportion of BRCA mutation carriers. In Latin America, only few founder mutations have been described. We screened 453 Chilean patients with hereditary breast cancer for mutations in BRCA1 and BRCA2. For recurrent mutations, we genotyped 11 microsatellite markers in BRCA1 and BRCA2 in order to determine a founder effect through haplotype analysis. We found a total of 25 mutations (6 novel) in 71 index patients among which, nine are present exclusively in Chilean patients. Our analysis revealed the presence of nine founder mutations, 4 in BRCA1 and 5 in BRCA2, shared by 2 to 10 unrelated families and spread in different regions of Chile. Our panel contains the highest amount of founder mutations until today and represents the highest percentage (78%) of BRCA1 and BRCA2 mutation carriers. We suggest that the dramatic reduction of Amerindian population due to smallpox and wars with Spanish conquerors, a scarce population increase during 300 years, and the geographic position of Chile constituted a favorable scenario to establish founder genetic markers in our population.

KW - BRCA1

KW - BRCA2

KW - Breast cancer

KW - Chile

KW - Founder mutation

UR - http://www.scopus.com/inward/record.url?scp=85030098079&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85030098079&partnerID=8YFLogxK

U2 - 10.18632/oncotarget.18815

DO - 10.18632/oncotarget.18815

M3 - Article

AN - SCOPUS:85030098079

VL - 8

SP - 74233

EP - 74243

JO - Oncotarget

JF - Oncotarget

SN - 1949-2553

IS - 43

ER -